Gaurav Shah, Rocket Pharmaceuticals CEO
September 20, 2022 07:38 AM EDTUpdated 07:50 AM
Deals
Cell/Gene Tx

Ren­o­va­cor ships its car­diac gene ther­a­py to Rock­et in $53M all-stock deal

Kyle LaHucik

Senior Reporter

Ren­o­va­cor want­ed to be in the clin­ic al­ready. The biotech ex­pect­ed an $11 mil­lion Se­ries A in sum­mer 2019 would bankroll an IND fil­ing for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times